Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Silexion Therapeutics Ltd.
Market Cap
$109274.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$97282.00
Gross Margin
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$70949.00
Gross Margin
-4864.71%
TTM Avg
-2432.36%
3Y Avg
-1195.54%
5Y Avg
-797.02%
Market Cap
$60340.00
Gross Margin
-60.46%
TTM Avg
-17.77%
3Y Avg
23.60%
5Y Avg
-269.73%
Market Cap
$30777.00
Gross Margin
-11.45%
TTM Avg
3.36%
3Y Avg
12.08%
5Y Avg
7.57%
Market Cap
$6033.00
Gross Margin
N/A
TTM Avg
26.93%
3Y Avg
28.12%
5Y Avg
27.47%
Market Cap
$356454.00
Gross Margin
61.90%
TTM Avg
-388.16%
3Y Avg
-189.98%
5Y Avg
-127.92%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Silexion Therapeutics Ltd. (SLXN) | $109274.00 | 0.00% | 0.00% | 0.00% | 0.00% |
| Psyence Biomedical Ltd. (PBM)vs › | $97282.00 | N/A | 0.00% | 0.00% | 0.00% |
| PRF Technologies Ltd. (PRFX)vs › | $70949.00 | -4864.71% | -2432.36% | -1195.54% | -797.02% |
| Akanda Corp. (AKAN)vs › | $60340.00 | -60.46% | -17.77% | 23.60% | -269.73% |
| Zhongchao Inc. (ZCMD)vs › | $30736.00 | 42.47% | 49.33% | 46.84% | 51.88% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30777.00 | -11.45% | 3.36% | 12.08% | 7.57% |
| NewGenIvf Group Limited (NIVF)vs › | $6033.00 | N/A | 26.93% | 28.12% | 27.47% |
| SciSparc Ltd. (SPRC)vs › | $246973.00 | 73.71% | 56.22% | 66.21% | 71.99% |
| Virax Biolabs Group Limited (VRAX)vs › | $356454.00 | 61.90% | -388.16% | -189.98% | -127.92% |
| Niki BioSolutions, Inc. (NIKI)vs › | $401484.00 | 0.00% | 0.00% | 2.16% | 0.42% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
